Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC).
Alberto Chiappori(Moffitt Cancer Center), M. S. Berger(Duke University), L. Johnetta Blakely, Marshall T. Schreeder(Clearview Cancer Institute), Helen J. Ross(Rush University), M. Moezi, Deepa S. Subramaniam(Georgetown University), J. Stephenson(Georgetown University), Quincy S. Chu, Ravi Salgia(City Of Hope National Medical Center)
Cited by 3
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k